Is It Time To Adjust The Pharma PDE Sales Force Optimization Model?

The question this white paper addresses is straightforward – will COVID-19 call for restructuring the long-standing pharma PDE (primary detail equivalent) sales force optimization model? The PDE model has been a go-to metric for sales response modeling, sales force optimization, and sales operations analyses for 20+ years. However, with the implications of COVID-19 on the global healthcare market, pharma companies are rethinking their commercial strategies, as noted in this white paper series.

This white paper provides a detailed review and assessment of only using PDEs in the post-COVID-19 sales response modeling, and the adjustments needed now in the pharma PDE sales force optimization model.

Dr. George A. Chressanthis is currently Principal Scientist at Axtria. He brings a unique combination of professional experiences into the analysis of strategic and operational issues affecting the biopharmaceutical industry.

Dr. Kedar Naphade is a Senior Principal at Axtria. He has over a dozen years of experience helping organizations create and institute innovative analytical decision making processes.

Contact us at insights@axtria.com with any questions.